Mnuchin told CNBC that he's confident President Donald Trump and President Xi Jinping can make progress in stalled trade talks.World Economyread more
President Donald Trump's administration hopes additional sanctions on Iran will force the country to negotiate.Politicsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Bitcoin surged as high as $12,919 in early morning trade Wednesday, to its highest level since January 2018.Technologyread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Tesla CEO Elon Musk sent out another email to his employees, pushing them to aim for a record number of vehicle deliveries to end the second quarter of 2019.Technologyread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Some 4 million people have fled the South American country since 2015 amid an economic meltdown.World Politicsread more
Japanese designer Undercover posted on its Instagram account a photo of protesters with the slogan "no extradition to China," the Financial Times reported.China Politicsread more
An imbalance in supply and demand is the root cause of recent pain for companies such as and , said Chip Davis, CEO of the Association for Accessible Medicines, the trade group for generic and biosimilar medicines.
"[Analysts are] pointing to some of the imbalances in the generic marketplace that haven't happened overnight, and that are continuing to evolve, but the reality is that the sustainable, robust competitive market is at risk now," Davis told CNBC on "Power Lunch."
He expects generic drugmakers will continue to feel pressure in the pharmaceutical market amid declining prices and nearly flat revenues.
Davis pointed to the "consolidation in the wholesalers and the retail pharmacy" as one cause for the deflationary environment, saying that there are "only three or four purchasers in the market, which are controlling 90-plus percent of the supply."
From June 2016 to June 2017, the number of generic prescriptions is nearly flat, up around 1 percent, while revenue is down 12 percent, he said.
Davis said he expects that if these conditions persist drugmakers will drop out of the market and that could potentially lead to a situation similar to the flu vaccine shortage in 2004. In that case, the number of suppliers shrank, resulting in an insufficient amount of the vaccine.
"We want to make sure we don't see the same type of concerns that we did previously in the vaccine sector," Davis said.
He also praised the new commissioner of the Food and Drug Administration, Dr. Scott Gottlieb.
"The robust level of competition per se is a good thing and new FDA commissioner Gottlieb should be applauded for his action plan … as we want to make sure that we don't have just competition but sustainable competition," Davis added.
The competitiveness of the market has been a flashpoint for generic drugmakers. Teva Pharmaceutical's interim
On Wednesday, in what CEO Heather Bresch called "a tough quarter."